Corcept Therapeutics (CORT) Earnings Date & Reports

Key Takeaways

• Corcept Therapeutics is expected to report third-quarter 2026 results in early November, following a second quarter in which shares surged after results topped estimates.
• Wall Street consensus points to revenue of roughly $324 million, which would mark a gain of about 56% from the $207.6 million reported a year earlier.
• Earnings-per-share (EPS) forecasts vary widely across data providers, with recent estimates ranging from about $0.65 to $0.81, reflecting uncertainty around the Lifyorli launch ramp.
• Investors will focus on Lifyorli's second full quarter of commercial sales after the ovarian cancer therapy generated $47.6 million in its debut quarter.
• Beyond the quarter, attention centers on the Dec. 17, 2026 regulatory decision date for relacorilant in Cushing's syndrome and on late-stage pipeline readouts due by year-end.

Earnings Context and Why It Matters

Corcept Therapeutics is transitioning from a single-product specialty pharmaceutical company into a multi-product business, making this quarterly report an important checkpoint for investors. The company's established Korlym franchise treats Cushing's syndrome, while its newly launched oncology drug Lifyorli (relacorilant) is targeting platinum-resistant ovarian cancer. Management has described Lifyorli's launch as one of the strongest oncology introductions it has seen, with more than 1,300 patients starting treatment in the first quarter of availability. With shares having climbed sharply in 2026, the upcoming report will test whether that momentum is backed by sustained commercial execution and whether the company remains on track toward its raised full-year revenue guidance of $1.1 billion to $1.2 billion.

Earnings Expectations

Analysts' consensus estimates for the third quarter call for revenue of approximately $324 million, up roughly 56% from the $207.6 million Corcept reported in the year-ago period. Earnings expectations are less uniform: consensus EPS figures range from about $0.65 (Zacks Research) to roughly $0.81 (MarketBeat), with other providers falling in between. The wide spread reflects differing assumptions about Lifyorli's uptake, operating expense growth, and share-count effects.

Several metrics will be closely watched. First is Lifyorli's sequential revenue growth, following its $47.6 million debut quarter. Second is the Korlym franchise, which generated $208.6 million in the second quarter, up 7.3% year over year. Third is operating-expense discipline, since selling, general, and administrative costs rose sharply in 2026 to support the oncology launch. Finally, investors will look for any commentary on the company's full-year 2026 revenue guidance of $1.1 billion to $1.2 billion.

Corcept's recent reporting history underscores the potential for outsized reactions. In its second-quarter report, earnings of $0.36 per share on $256.1 million in revenue far exceeded consensus, and shares jumped more than 20% in after-hours trading.

AI Screener

For investors looking to identify opportunities beyond a single earnings event, Tickeron's AI Screener offers an AI-powered stock and ETF discovery tool designed to filter the market more efficiently. The screener lets traders and investors scan thousands of stocks and ETFs using customizable criteria such as industry, market capitalization, technical indicators, price patterns, volatility, and performance metrics. By surfacing AI-driven signals, it helps users spot trade ideas, trending stocks, breakout candidates, and emerging market opportunities faster than manual screening. Whether you are tracking biotech momentum or broadening your watchlist across sectors, the AI Screener can help you organize your research and monitor the setups that matter most to your strategy.

Market Reaction and Investor Sentiment

Sentiment heading into Corcept's third-quarter report remains constructive, though expectations are elevated. The stock has appreciated sharply in 2026, supported by the Lifyorli approval, strong early launch metrics, and raised guidance. Following the second-quarter beat, shares surpassed a 52-week high, reflecting investor enthusiasm for the company's oncology expansion.

That optimism also creates risk. With estimates varying widely and the shares trading at a premium valuation, a report that merely meets expectations—or a Lifyorli trajectory that disappoints—could trigger volatility. Key risk factors include the pace of new patient starts, payer access dynamics, and rising operating expenses tied to the launch. Investors will also listen closely to management's commentary on the relacorilant new drug application (NDA), a formal request for FDA approval, for Cushing's syndrome ahead of its December decision date.

Forward Outlook and Key Factors to Monitor

Looking beyond the third-quarter print, several catalysts will shape Corcept's trajectory. The most significant is the U.S. Food and Drug Administration's (FDA) decision on relacorilant for Cushing's syndrome, with a target action date of Dec. 17, 2026 under the Prescription Drug User Fee Act (PDUFA). Approval would expand the company's endocrinology franchise and add a second indication for the molecule already sold as Lifyorli in oncology.

Pipeline readouts are also approaching. Corcept expects results from the first arm of its BELLA study—evaluating relacorilant plus nab-paclitaxel and bevacizumab in platinum-resistant ovarian cancer—by the end of 2026. Data from the MONARCH study of miricorilant in metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease, are also expected by year-end. Positive results could meaningfully broaden the company's addressable market.

Operationally, investors should monitor Lifyorli's revenue ramp, Korlym prescription trends, and whether expense growth begins to moderate as the launch matures. Corcept's balance sheet remains strong, with cash and investments of $544.6 million at the end of the second quarter, providing flexibility to fund development and commercialization. The company's ability to translate its growing commercial footprint into profitability will remain a central theme in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations